r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid has been researched along with flufenamic acid in 1 studies
| Studies (r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid) | Trials (r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid) | Recent Studies (post-2010) (r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid) | Studies (flufenamic acid) | Trials (flufenamic acid) | Recent Studies (post-2010) (flufenamic acid) |
|---|---|---|---|---|---|
| 17 | 4 | 9 | 1,058 | 69 | 202 |
| Protein | Taxonomy | r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid (IC50) | flufenamic acid (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 0.76 | |
| Transthyretin | Homo sapiens (human) | 2.9 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.615 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.112 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 1.4901 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 1.3467 | |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | 2.64 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirschfield, GM | 1 |
1 review(s) available for r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid and flufenamic acid
| Article | Year |
|---|---|
Amyloidosis: a clinico-pathophysiological synopsis.
Topics: Acetylglucosamine; Amyloid; Amyloid beta-Protein Precursor; Amyloidosis; Amyloidosis, Familial; Carboxylic Acids; Flufenamic Acid; Humans; Immunotherapy; Peptides; Prealbumin; Protein Binding; Protein Folding; Protein Precursors; Proteoglycans; Pyrrolidines; Serum Amyloid P-Component | 2004 |